MILITIA HILL VENTURES, Philadelphia PA, bringing together transformational science, proven industry and medical expertise as well as high-level capital
Militia Hill Ventures (MHV) is a company builder. Its mission is to build great companies that discover and develop effective solutions to health problems, products that make a remarkable difference for patients. MHV fulfills this mission by bringing together transformational science, proven industry and medical expertise as well as high-level capital. Thus, MHV provides resources, support and operational talent as needed to allow its companies to flourish and bring new therapies, diagnostics, and devices to patients.
Militia Hill Ventures creates and develops exceptional life sciences companies. MVV accelerates life science innovations through a broad network, relationships, and domain expertise. It creates high-quality, fast-growing companies by catalyzing cutting-edge science, proven management, and successful life sciences. MHV believes that this active; “build” approach is the most effective way to build great companies with the capability to develop new life-saving therapies for patients and to bring high-value returns to investors.
Militia Hill Ventures enables these select portfolio companies and teams to access an abundance of resources, including preferred access to the expertise, capital, relationships, and infrastructure necessary for success. MHV is expanding the number of high-quality life sciences businesses and products in the greater Philadelphia area, increasing the return for investors in these businesses and speeding the development of life-saving products for patients.
Current (as of 2018) portfolio of Militia Hill Ventures includes Talee Bio, Immunome, and Tmunity. Talee Bio is developing a gene therapy for cystic fibrosis (CF). To our knowledge, it is the first curative treatment for this disease. In collaboration with drug development experts, Talee Bio has developed a novel transgene and several innovations using a well-characterized delivery vector to overcome challenges that have previously limited the clinical effectiveness of gene therapy for CF. Immunome uses precision medicine to develop new solutions for cancer treatment. the approach of Immunomeis to utilize the human immune system to discover and develop novel cancer-specific targets by identifying B-lymphocytes from patients who already have shown an effective immune response against their cancer. Finally, Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.
Militia Hill Ventures
3025 Market St, Suite 140, Philadelphia, Pennsylvania, PA, United States